Loxo Oncology
在场
是其中之一......
- Forbes Global 2000 (#174);
- Fortune 500 (#127);
- Global Fortune 500 (#455);
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Eli Lilly 是一家在股票代码 LLY (US) 下上市的公司。
Eli Lilly 在 18 个国家有直接业务。Eli Lilly 拥有 25家子公司，其中包括 Dice Therapeutics、Eli Lilly APAC 和 Eli Lilly Argentina。
他们在：
涉及Eli Lilly的并购和融资。
- Eli Lilly 已收购 Morphic Therapeutic (公布2024八月20号).
- Eli Lilly has announced the acquisition of Point Biopharma (公布2023十二月5号).
- Eli Lilly has announced the acquisition of Point Biopharma (公布2023十月6号).
- Eli Lilly 已收购 Versanis Bio (公布2023八月15号).
- Eli Lilly has announced the acquisition of Versanis Bio (公布2023七月18号).
- Eli Lilly has announced the acquisition of Sigilon Therapeutics (公布2023六月30号).
- Eli Lilly has announced the acquisition of Dice Therapeutics (公布2023六月22号).
- Eli Lilly 已收购 Akouos (公布2022十二月2号).
- 查看更多"Eli Lilly"相关新闻 Hide news involving Eli Lilly
高管
查看带有其 15 名主要高管的组织结构图
Loxo Oncology 搜索最多的简介
- Jacob Van Naarden, Chief Executive Officer
- Philip Johnson, Senior Vice President, Development
- David Hyman, Chief Medical Officer
高管在Eli Lilly变化
- Thomas FuchsThomas Fuchs 将于202410月20作为 Chief Artificial Intelligence Officer 加入公司 (新闻发布的2024十月9号).
- Marschall Runge, Director, 将于 20248月30 退休 (新闻发布的2024八月20号).
- Gordon Brooks 曾任 Group Vice President, Controller and Corporate Strategy, 现升职为 Interim Chief Financial Officer and Group Vice President, Controller and Strategy (新闻发布的2024七月22号).
创建提醒
跟踪 Loxo Oncology 的高管变动
健康
Eli Lilly 拥有 1,938 家竞争者，其中包括 Siemens Healthineers (德国)、IQVIA (美国(美洲)) 和 Nestlé Health Science (瑞士)。
Popular M&A news in 健康
- Oshi Health 刚刚宣布为 60 筹款数百万美元。 (公布2024十月18号).
- Glooko 刚刚宣布为 100 筹款数百万美元。 (公布2024十月14号).
- Abridge 刚刚宣布为 250 筹款数百万美元。 (公布2024十月14号).
健康 行业的其他推荐联系人
消息
Loxo Oncology 的最新新闻稿
- Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction | Investor Relations
- Lilly Announces Agreement To Acquire Loxo Oncology | Investor Relations
- Loxo Oncology Announces Initiation of Phase 1/2 Clinical Trial for Highly Selective, Non-Covalent BTK Inhibitor, LOXO-305 | Investor Relations
- FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2) | Investor Relations
- Loxo Oncology Reports Third Quarter 2018 Financial Results | Investor Relations
- https://ir.loxooncology.com/docs/press-releases/2376151-Loxo-oncology-reports-third-quarter-2018-financial-results-.pdf
- Loxo Oncology to Participate in Upcoming Investor Conferences | Investor Relations
- Loxo Oncology to Announce Third Quarter 2018 Financial Results | Investor Relations
- Loxo Oncology Announces Larotrectinib Clinical Update in Patients with TRK Fusion Cancers at the European Society for Medical Oncology 2018 Congress | Investor Relations
- Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292 for the Treatment of RET Fusion-Positive Thyroid Cancer | Investor Relations
- View more press releases Close
关于 Loxo Oncology 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 David Hyman 
